Could Oral Paclitaxel Plus Encequidar Be Offered as Outpatient mBC Treatment?
Gerardo Umanzor, MD, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 pandemic.
Gerardo Umanzor, MD, medical oncologist with Centro Oncologico Integral in San Pedro Sula, Honduras, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous (IV) formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 (COVID-19) pandemic.
In the phase 3 KX-ORAX-001 clinical trial (NCT02594371), progression-free survival (PFS) and overall survival (OS) improvement were achieved with the combination of oral paclitaxel plus encequidar versus intravenous paclitaxel plus encequidar. Umanzor says that considering the limitations of access to care during the pandemic, the idea of an outpatient treatment option is appealing for both physicians and patients.
A shift from IV infusions may also be a more cost-effective strategy for treating patients explains Umanzor, because inpatient care tends to be more costly compared with outpatient care.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
